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LEWIS, M. E., H. KHACHATURIAN AND S. J. WATSON. Combined autoradiographic-immunocytochemical analysis of 
opioid receptors and opioid peptide neuronal systems in brain. PEPTIDES 6: Suppl. 1, 37--47, 1985.--Using adjacent section 
autoradiography-immunocytochemistry, the distribution of [3H]naloxone binding sites was studied in relation to neuronal 
systems containing [Leu]enkephalin, dynorphin A, or/3-endorphin immunoreactivity in rat brain. Brain sections from 
formaldehyde-perfused rats show robust specific binding of [3H]naloxone, the pharmacological ~-like) properties of which 
appear unaltered. In contrast, specific binding of the 8 ligand [3H]D-AlaZ,D-LeuS-enkephalin was virtually totally eliminated as a 
result of formaldehyde perfusion. Using adjacent section analysis, we have noted associations between [3H]naloxone binding 
sites and one, two, or all three opioid systems in different brain regions; however, in some areas, no apparent relationship could 
be observed. Within regions, the relationship was complex; for example, in caudate-putamen, patches ofopioid receptors did not 
correspond to the distribution of enkephalin immunoreactivity, but there was a correspondence between subeallosal streaks of 
binding sites and enkephalin. The complexity of the association between [3H]naloxone binding sites and the multiple opioid 
systems, and previous reports of colocalization of Ix and K receptors in rat brain, are inconsistent with a simple-one-to-one 
relationship between a given opioid precursor and opioid receptor subtype. Instead, since differential processing of the three 
precursors gives rise to peptides of varying receptor subtype potencies and selectivities, the multiple peptide-receptor relation- 
ships may point to a key role of post-translational processing in determining the physiological consequences of opioid 
neurotransmission. 
Opioid receptor autoradiography Enkephalin Dynorphin fl-Endorphin 
THE pharmacological and biochemical evidence for multiple 
subtypes of  opioid receptors has reached overwhelming pro- 
portions [5, 17, 19], but the physiological significance of  this 
multiplicity remains obscure. One simple and elegant 
possibility is that the receptor  subtypes serve to discriminate 
between the multiple forms of endogenous opioid peptides. 
Thus, the multiple receptors could be differentially coupled 
to neural systems containing one of  the three opioid peptide 
precursors:  (1) proopiomelanocort in [32, 47, 48], which gives 
rise to/3-endorphin and its NH2-terminally acetylated and/or 
COOH-terminally shortened forms; (2) proenkephalin [7, 13, 
38], which contains four copies of [Met]enkephalin and 
single copies of  [Leu]enkephalin, [Met]enkephalin-Argt-Phe 7 
and [Met]enkephalin-Argt-Glyr-Leu s, and gives rise to 
longer enkephalin-containing peptides,  such as BAM-12P, 
BAM-22P, and Peptides E and F; (3) prodynorphin [20], 
which gives rise to three peptides containing the 
[Leu]enkephalin sequence:  a-/fl-neo-endorphin, dynor-  
phin A, and dynorphin B. Since these peptides all share the 
NHz-terminus tetrapeptide sequence (Tyr-Gly-Gly-Phe) cod- 
ing for opioid receptor  activation, the COOH-terminus se- 
quence may code for which receptor  subtype is to be occu- 
pied. Since in vitro studies have shown the pentapeptide 
enkephalins to preferentially bind the 6 subtype [31], while 
prodynorphin-related peptides have usually been reported to 
exhibit selectivity for the K subtype ([6, 8, 64; but see [44]), it 
might be predicted that enkephalin- and dynorphin- 
containing neurons would be associated, respectively,  with 8 
and K opioid receptor  subtypes. However ,  since/3-endorphin 
binds equally well to the tt and 8 subtypes in vitro [31], but 
not to the K subtype [46], an association of  
proopiomelanocortin neurons with both/x and 8 sites would 
be predicted. 
Direct testing of these predictions, using presently avail- 
able techniques, requires that all three classes of  opioid 
neurons be discriminated immunocytochemical ly  in 
anatomical relation to autoradiographically detected opioid 
receptor  subtypes. Since enkephalin and dynorphin neurons, 
in particular, are anatomically contiguous or relatively 
nearby in many brain regions [21,58], it is critical that the 
antisera used discriminate between these neurons and that 
the receptors  are localized in close relationship to the 
immunoreactive neuronal structures. We have recently re- 
ported that adjacent sections from formaldehyde-perfused 
rat brain can be processed for immunocytochemical lo- 
calization of  [Leu]enkephalin and autoradiographic detec- 
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tion of [aH]naloxone-labeled opioid receptors [27]. This find- 
ing was confh'med for rhesus monkey brain [28], and an 
anatomical relationship was shown between [3H]naloxone 
binding sites and all three opioid systems in different brain 
regions. We now present f'mdings showing that the phar- 
macological properties of [3H]naloxone binding sites in rat 
brain are unchanged by formaldehyde perfusion, and de- 
scribe the anatomical relationship of these sites to neuronal 
systems immunoreactive for molecules derived from the 
three opioid precursors. 
METHOD 
Adult male Sprague-Dawley rats were anesthetized with 
sodium pentobarbital and given stereotoxic microinjections 
of colchicine (150-300/~g/10/~1 0.9% saline) into the lateral 
ventricle, or left untreated. Forty-eight hours later, the rats 
were anesthetized with sodium pentobarbital (50 mg/ml, in- 
traperitoneally), packed in ice, and the cardiovascular sys- 
tem was flushed with 50 ml of ice-cold 0.9% saline through 
the left ventricle, with the right atrium cut open. The ventri- 
cles were excised and a cannula was inserted into the aorta, 
through which the animal was peffused with ice-cold 0.1 M 
phosphate-buffered 4% formaldehyde (pH 7.4, prepared 
from depolymerized paraformaldehyde) at 140 mm Hg for 30 
minutes. The brains were removed, blocked in coronal or 
parasagittal planes, and incubated overnight at 4°C in 0.1 M 
phosphate-buffered saline (PBS, pH 7.4) containing 15% su- 
crose. The brain pieces were frozen by immersion in -40°C 
isopentane for 30-40 seconds, embedded in powdered dry 
ice, and stored at -70°C. Sections were cut at 20/~m thick- 
ness in a cryostat at -20°C and thaw-mounted onto subbed 
slides which were stored at -70°C until use. Sections were 
similarly cut from the brains of unperfused rats, but were 
vacuum-dried at 4°C for 2 hours to facilitate their adhesion to 
the slides [16]. 
For peroxidase-antiperoxidase immunocytochemistry 
[25], frozen tissue sections were allowed to air-dry at room 
temperature and were then incubated at 37°C with normal 
goat serum (NGS, from GIBCO) at a dilution of 1/30 for 5 to 
10 minutes, followed by primary rabbit antiserum (i.e., 
anti-fl-endorphin, anti-[Leu]enkephalin, and anti-dynorphin 
A sera), diluted with 0.02 M PBS containing 0.3% Triton 
X-100, for 1 hour at 37°C and overnight (approximately 24 
hours) at 4°C. Possible cross-reactivity of each antiserum 
was tested by incubating control sections with antiserum 
preadsorbed with 1-20 /~M concentrations of the peptide 
used as antigen as well as with peptides having related amino 
acid sequences (see [57] for antiserum specificities). The fol- 
lowing day, the sections were washed in three changes of 
PBS (10 minutes each) and incubated with NGS for 10 min- 
utes at 37°C,  followed by goat-antirabbit serum 
(Sternberger-Meyer) at 1/100 dilution for 30 minutes at 37°C 
and then overnight at 4°C. The next day, the sections were 
washed in PBS and incubated with NGS for 10 minutes at 
37°C, and then with rabbit antihorseradish peroxidase serum 
at 1/200 dilution for 40 minutes at 37°C. The sections were 
then washed in PBS and incubated with 4/zg/ml horseradish 
peroxidase (Sigma, Type VI) for 40 minutes at 37°C. The 
histochemical reaction for peroxidase was carried out by in- 
cubating the sections in 200 ml of PBS containing 0.03% 
H202 and 0.125 mg/ml diaminobenzidine (Sigma) for 15 
minutes at room temperature, with constant stirring. The 
sections were then washed in distilled water, briefly osmi- 
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FIG. 1. Effect of formaldehyde perfusion on the pharmacological 
characteristics of specific [3H]naloxone binding in striatal sections. 
Filled symbols: sections from unperfused rat brains. Open symbols: 
sections from 4% formaldehyde-perfused rat brains. 
through ascending concentrations of ethanol and xylenes, 
and coverslipped in Permount. 
Sections adjacent to those processed for im- 
munocytochemistry, or sections from unperfused rat brain, 
were processed for opioid receptor autoradiography using 
the method of Herkenham and Pert [14,16]. The slide- 
mounted sections were incubated in (a) 0.05 M Tris.HCl (pH 
7.4) containing 1 nM [3H]naloxone (40 Ci/mmol; New Eng- 
land Nuclear) and 100 mM NaCI for 2 hours at 4°C, or (b) 
0.05 M Tris.HCl (pH 7.4) containing 1 nM 
[3H]D-Ala2-D-LeuS-enkephalin (40 Ci/mmol; Amersham), 
with or without 3 mM Mn (OAc)2, 100 mM NaCI and 2/zM 
guanosine triphosphate, for 30 minutes at 25 °. These incuba- 
tion conditions are similar to those used to label apparent # 
and ~ opioid receptors, respectively, in previous studies of 
rhesus monkey [29] and rat [30] cerebral cortex, and also rat 
striatum [4, 15, 36]. To evaluate nonspecific binding, some 
slides were incubated in the the above media which also 
included 1/zM levorphenol. The pharmacological properties 
of the binding sites were evaluated by carrying out displace- 
ment studies with different unlabeled opiates, followed by 
liquid scintillation counting of the sections. The incubations 
were terminated by transferring the slides through five rinses 
(20 seconds each, in 200 ml at 4°C) of 0.1 M PBS (pH 7.4) for 
the [3H]naloxone-incubated slides or 0.05 M Tris.HCl (pH 
7.4) for the [3H]D-Ala~-D-LeuS-enkephalin-incubated slides, 
and then drying the sections under a stream of cold air. 
RESULTS 
As reported before [27], brain sections from 
formaldehyde-perfused rats exhibited high specific binding 
(85% of total binding) of [3H]naloxone. When striatal-level 
brain sections from formaldehyde-perfused and unperfused 
rats were labelled with [3H]naloxone, specific binding was 
inhibited equivalently in both tissues by levorphanol, and 
less potently by morphine, while dextrorphan was ineffective 
(Fig. 1). Despite some loss of [3H]naloxone binding sites 
[27], the pharmacological properties of the remaining sites do 
not appear to have been dramatically altered. However, vir- 
tually all specific binding of [aH]D-Ala2-D-LeuS-enkephalin 
was eliminated in the perfused tissue, preventing an adjacent 
section analysis of 8 sites in relation to the opioid im- 
munoreactive systems. 
Anatomically, a large number of brain regions contain 
opioid peptides and [3H]naloxone binding sites. By analyzing 
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FIG. 2. Caudate-putamen. Patches of [3H]naloxone binding sites are shown in A and in higher magnification in C. Corresponding adjacent 
sections B and D depict [Leu]enkephalin immunoreactivity. Arrows in A and B indicate the subcallosal streak; arrowheads in B demarcate 
terminal immunoreactivity in the globus pallidus, v: ventricle; ic: internal capsule. Mag. A, B: 64x; C, D: 160×. 
adjacent brain sections, we have noted many associations 
between the distribution of these binding sites and one, two 
or all three opioid peptides. In contrast, we have also noted a 
distinct lack of such associations in other brain regions. In 
the following paragraphs, we will present some of our obser- 
vations on the distributions of fl-endorphin, [Leu]enkephalin, 
and dynorphin A immunoreactive neurons and [3H]naloxone 
binding sites at several levels of the rat brain and spinal cord. 
Telencephalon 
In the cerebral cortex, [3H]naloxone binding sites show 
striking regional differences in laminar distribution, although 
most areas have concentrations of sites in the most super- 
ficial part of layer I and in layer VI, with an intermediate 
band of sites having a region-specific laminar localization 
(see [30] for a detailed, quantitative analysis). The prelimbic 
and cingulate cortex exhibits a distinctive trilaminar pattern 
of [3H]naloxone binding sites in layers I, III, and VI. 
[Leu]enkephalin immunoreactive perikarya are present in 
the submolecular laminae, including layer VI, which con- 
tains a particularly high density of [3H]naloxone binding 
sites. Motor and sensory cortical areas generally exhibit a 
lower density of sites and correspondingly fewer enkephalin 
immunoreactive perikarya, which are present in layers II-III  
and to a lesser extent in layers V-VI (see [24,33]). In 
piriform cortex, [3H]naloxone binding sites are concentrated 
in layer III at the transition area to claustrum, while 
enkephalin immunoreactive perikarya are mostly present in 
layer II and may give rise to medially coursing immunoreac- 
tive fibers. A similar relationship of enkephalin perikarya 
and [3H]naloxone binding sites is seen in entorhinal cortex. 
Dynorphin immunoreactive perikarya were observed mainly 
in layer II of entorhinal cortex, although immunoreactive 
fibers were often detected traversing layers I-III  in most 
areas of cerebral cortex. 
A very dense distribution of [3H]naloxone sites has been 
noted in the striatal nuclear complex. These are for the most 
part in the form of large patches in the caudate-putamen, as 
well as a distinct subcallosal streak within the latter complex 
(Fig. 2). Also within caudate-putamen, there exist both 
enkephalinergic and dynorphinergic neurons which project 
to the globus pallidus and possibly elsewhere in the brain, 
notably the substantia nigra. [Leu]enkephalin-containing 
processes form distinct, yet small immunoreactive patches 
distributed in ventromedial regions of the caduate-putamen, 
adjacent to the globus pallidus. Additionally, a distinct sub- 
callosal streak of [Leu]enkephalin immunoreactivity is seen 
in this nuclear complex. Upon analyzing adjacent sections 
processed for [3H]naloxone autoradiography and 
[Leu]enkephalin immunoreactivity, no correspondence was 
noted between the large receptor-rich patches and the rela- 
tively small enkephalin-rich patches (Fig. 2). In fact, in some 
areas a negative correlation was noted between the distribu- 
tion of binding sites and peptide. By contrast, the subcallosal 
streak of binding sites corresponds precisely to that of 
[Leu]enkephalin immunoreactivity in the same regions (Fig. 
3). The globus pallidus, an area of particularly rich 
[Leu]enkephalin and dynorphin A terminal immunoreactiv- 
ity, is virtually devoid of [aH]naloxone binding sites. 
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FIG. 3. Caudate-putamen. These adjacent sections illustrate [3H]naloxone binding (A) and 
[Leu]enkephalin immunoreactivity (B). Note the correspondence between the thick streak of binding 
sites and immunoreactivity in the subcallosal streak, cc: corpus callosum. Mag.: 200x. 
Elsewhere in the telencephalon, the central nucleus of 
amygdala is particularly rich in all three opioid peptides. 
Both [Leu]enkephalin and dynorphin A neuronal perikarya 
and processes are seen in this nucleus, and a moderately 
dense distribution of fl-endorphin immunoreactive processes 
also innervate the central nucleus. In adjacent sections, the 
latter nucleus also appears to be rich in [3H]naloxone binding 
sites, corresponding well with the distribution of the opioid 
peptide immunoreactivities. 
In the hippocampal formation, [Leu]enkephalin and 
dynorphin A immunoreactivity was seen in the mossy fiber 
projections from the dentate gyrus to the hippocampus 
proper. Interestingly, the dentate gyrus granule cell layer 
and the pyramidal cell layer of hippocampus contain a rela- 
tively high density of [3H]naloxone binding sites. Since the 
mossy fibers innervate the pyramidal cells, the existence of 
opiate binding sites on these cells correlates well with the 
opioid nature of the mossy fibers. 
Diencephalon 
Compared to the striatum, thalamus, and inferior col- 
liculus, the hypothalamus is not an area particularly enriched 
in [3H]naloxone binding sites. However, moderate levels of 
[aH]naloxone binding are noted in the medial basal hypothal- 
amus of the rat, concentrated especially in the median emi- 
nence. Various hypothalamic nuclei contain neuronal 
perikarya which produce/3-endorphin, [Leu]enkephalin, or 
dynorphin A. In fact, opioid peptide-producing neurons are 
concentrated heavily in the hypothalamus. It is important to 
note that these opiatergic hypothalamic neurons project 
either to the median eminence or to extrahypothalamic brain 
regions, while only a few hypothalamic nuclei contain mod- 
erately dense innervation patterns. These include the dor- 
somedial and periventricular nuclei which contain 
/3-endorphin projections from the arcuate perikarya, and 
ventromedial nucleus which contains [Leu]enkephalin and 
dynorphin A perikarya as well as terminals. None of these 
nuclei are particularly rich in [3H]naloxone binding sites. 
However, the median eminence, as mentioned, contains 
moderate levels of these sites. Immunoreactive processes of 
all three opioid peptides are also seen in the median emi- 
nence surrounding the portal capillaries. Therefore, the 
existence of [3H]naloxone sites in this region corresponds 
well with the known neuroendocrine functions of the opioid 
peptides. 
In the thalamus, the distribution of [3H]naloxone binding 
sites is particularly dense in specific nuclear regions. Al- 
though in general the distribution of opioid peptides is not 
particularly heavy in thalamic nuclei, some striking correla- 
tions can be noted. A distinct bundle of immunoreactive 
/3-endorphin fibers traverses and perhaps innervates the 
periventricular thalamic nucleus, which also contains mod- 
erate levels of immunoreactive [Leu]enkephalin terminals. 
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FIG. 4. Medial habenula. A and B are adjacent sections depicting [3H]naloxone binding and 
[Leu]enkephalin immunoreactivity, respectively. Dashed lines in A outline the tissue boundaries corre- 
sponding to B. sm: stria medullaris; v: ventricle. Mag.: 200×. 
Likewise, [3H]naloxone site density in this nucleus is 
pronounced and corresponds well with peptide distribution 
in adjacent sections. Other thalamic regions which contain 
both binding sites and [Leu]enkephalin fibers in good corre- 
spondence include the anterodorsal and central medial nuclei. 
Other areas of dense binding site distribution do not contain 
fl-endorphin or dynorphin A, but are sparsely populated by 
[Leu]enkephalin fibers. In the habenula there is an excellent 
correlation between the distribution of enkephalin im- 
munoreactive fibers and [3H]naloxone binding sites (Fig. 4). 
Mesencephalon 
Several areas of the mesencephalon contain a dense dis- 
tribution of [3H]naloxone binding sites. Some of these areas 
are also rich in opioid peptide immunoreactivity. Ventrally, 
the substantia nigra pars compacta is rich in binding sites, 
but poor in opioid peptide content. Only sparse 
[Leu]enkephalin immunoreactivity is seen in the pars com- 
pacta. In contrast, the pars reticulata of substantia nigra, 
which contains a low density of [3H]naloxone sites, is par- 
ticularly rich in dynorphin A immunoreactivity. 
The interpeduncular nuclear complex is an area of excep- 
tional correspondence between the distribution of 
[3H]naloxone binding sites and [Leu]enkephalin im- 
munoreactive perikarya and fibers (Fig. 5). In adjacent sec- 
tions, almost identical, dense patterns of distribution of bind- 
ing sites and immunoreactive fibers and terminals are seen in 
several, but not all, subdivisions of this nucleus. Generally, 
this correspondence is best in the rostral and central subnu- 
clei (see Fig. 5). Interestingly, the interpeduncular nucleus is 
devoid of fl-endorphin and dynorphin A immunoreactivity. 
More dorsally, a moderately dense distribution of 
[3H]naloxone sites is noted in the periaqueductal gray (Fig. 
6). This distribution is uniform and upon serial section 
analysis corresponds well with the distribution of 
fl-endorphin fibers and terminals ventrally, but not dorsally. 
Likewise, immunoreactive [Leu]enkephalin and dynorphin 
A neurons also exist in ventral periaqueductal gray as well as 
laterally in the mesencephalic reticular formation. Im- 
munoreactive fibers and terminals of [Leu]enkephalin and 
dynorphin A neurons are distributed somewhat more uni- 
formally throughout the periaqueductal gray, but also tend to 
be more concentrated ventrally. 
Within the colliculi, a laminated pattern of [3H]naloxone 
binding sites is noted in the superior colliculus with the most 
superficial layer being particularly rich in sites. The inferior 
collicuhis contains a uniformly dense distribution of binding 
sites. Immunoreactive fibers belonging to all three opioid 
peptide systems are also seen in both the superior and in- 
ferior colliculi, with the latter receiving a relatively denser 
innervation by fl-endorphin and [Leu]enkephalin fibers and 
terminals. However, the laminations in binding site distribu- 
tion in the superior colliculus do not correspond to the pat- 
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FIG. 5. Interpeduncular nuclear complex. Binding sites for [aH]naloxone are shown in A, 
while immunoreactive [Leu]enkephalin perikarya and fibers in an adjacent section are 
shown in B. ml: medial lemniscus. Mag.: 80x. Note the correspondence between im- 
munoreactivity and binding sites in the rostral (r) and central (c) subnuclei, but the 
relative abundance of sites and paucity of immunoreactivity in the lateral (I) subnucleus. 
tern of  immunoreactivity seen with any of the opioid pep- 
tides. 
Pons and Medulla 
The densest  areas of  [3H]naloxone binding site distribu- 
tion in the pons occur in the dorsal tegmental regions. The 
parabrachial  nucleus is rich in binding sites as is the nucleus 
locus coeruleus. The parabrachial  nuclei also exhibit a dense 
pattern of  fl-endorphin fiber immunoreactivity. Further- 
more, both [Leu]enkephalin and dynorphin A containing 
neuronal perikarya and processes are also seen in the para- 
brachial nuclei, which upon serial section analysis appear  to 
form separate neuronal populations. Interestingly, 
[3H]naloxone binding site density in this nucleus is uniform 
and corresponds well with the distribution of all three opioid 
peptides (Fig. 7). The locus coeruleus is also very rich in 
[3H]naloxone sites. Yet this nucleus contains only a light 
density of/3-endorphin and [Leu]enkephalin immunoreac- 
tivity. 
In the medulla obiongata, the nucleus tractus solitarius 
shows a dense distribution of  [3H]naloxone binding sites. All 
three opioid peptides are also seen in this nucleus in both 
neuronal perikarya and fibers. The correspondence between 
the distribution of [Leu]enkephalin immunoreactivity and 
binding site distribution is particularly well outlined in the 
more caudal areas of this nucleus (Fig. 8). Another medul- 
lary area of particularly good correlation between the distri- 
butions of binding sites and [Leu]enkephalin is the nucleus of 
the spinal tract of  the trigeminal nerve (Fig. 8). Upon serial 
section analysis, both peptide immunoreactivity and binding 
sites are concentrated in the outermost laminae of this nu- 
cleus which in actuality are the rostral continuation of  the 
spinal cord dorsal horn laminae I and II. These laminae also 
exhibit dense [Leu]enkephalin and [aH]naloxone binding site 
distribution. 
DISCUSSION 
We have described anatomical relationships between 
multiple opioid immunoreactive neural systems and 
[3H]naloxone binding sites in adjacent sections from 
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FIG. 6. Periaqueductal gray. This series of four adjacent sections demonstrates the relationship between serotonergic dorsal raphe neurons 
(A), [Leulenkephalin immunoreactive perikarya and fibers (B), [3H]naloxone binding sites (C) and/3-endorphin immunoreactive fibers (D). aq: 
aqueduct. Mag.: 160x. 
formaldehyde-perfused rat brain• The pharmacological 
properties of  these binding sites were evidently unchanged 
by perfusion, as indicated by unaltered displacement poten- 
cies of several compounds. The pharmacological relevance 
of the binding sites is indicated by the excellent correlation 
between the pharmacological efficacy of a series of  opiate 
compounds and their potency in displacing [aH]naloxone bind- 
ing from brain tissue sections [4,16]• The identity of  these 
binding sites a s / z  rather than 8 or r in rat brain has been 
indicated by appropriate structure-activity studies [4, 16, 42]. 
The survival of [3H]naloxone binding sites following for- 
maldehyde perfusion is in contrast to the virtually total loss 
of  [aH]D-AlaZ,D-Leu~-enkephalin binding. The differential 
sensitivities to formaldehyde of the binding of these two 
ligands may reflect a difference between the chemical prop- 
erties of  the/~ and 8- opioid receptors, as suggested by Hiller 
e t  al .  [18], who reported differential inhibition of /x  and 8 
ligand binding in the presence of alcohols• Alternatively, it is 
possible, if/x and 8 sites occur as interconverting forms of a 
single receptor [4], that formaldehyde has "fixed" opioid 
receptors into their/x conformation. We cannot discriminate 
these possibilities at present, but suggest that formaldehyde 
may prove to be a useful reagent for investigators who wish 
to explore the physicochemical properties of opioid receptors. 
The survival of  [3H]naloxone binding following for- 
maldehyde perfusion has permitted us to carry out receptor 
autoradiographic and opioid peptide immunocytochemical 
studies on adjacent sections from the same brain. While it is 
possible to obtain general information about the anatomical 
relationships between endogenous ligands and their recep- 
tors by comparing tissue sections from brains processed dif- 
ferentially for immunocytochemistry and autoradiography 
[52,54], such comparisons are intrinsically difficult due to 
complexities in receptor distribution, and, in the case of the 
opioid systems, the anatomical proximity of proenkephalin 
and prodynorphin neurons• Also, while the use of nonselec- 
tive opioid ligands, such as [3H]diprenorphine [1-3, 52] and 
[3H]D-AlaZ,Met-enkephalinamide [54] may be useful in 
providing a global picture of opioid receptor distribution, the 
use of more selective ligands should aid in determining rela- 
tionships between different receptor subtypes and multiple 
opioid systems. In this aim, it is especially critical to use 
antisera which clearly discriminate opioid systems contain- 
ing different precursors, since these precursors give rise to 
opioids of  varying receptor subtype selectivities (see Intro- 
duction). The use of antisera which crossreact with peptides 
from two different opioid precursors (e.g., [54]) can confuse 
the issue of the differential localization of neurons containing 
these precursors (see [21]) as well as the issue of the relation- 
ship of these neurons to different opioid receptors. The pres- 
ent study utilized [3H]naloxone, a relatively /x-selective 
ligand in rat brain, and [Leu]enkephalin, dynorphin A, and 
/3-endorphin antisera which were previously shown to be 
non-crossreactive with peptides from the other precursors 
[21-25, 57, 58]. 
Using adjacent section analysis, we have noted associa- 
tions between [3H]naloxone binding sites and one, two or all 
three opioid systems in many brain regions; in others, no 
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FIG. 7. Lateral parabrachial nucleus. These three adjacent sections show immunoreac- 
tive [Leu]enkephalin perikarya in A, [aH]naloxone binding sites in B, and dynorphin A 
immunoreactive perikarya in C. The positions of [Leu]enkephalin and dynorphin A 
immunoreactive perikarya are separate in this nucleus, while the terminal immunoreac- 
tivity of both peptides corresponds to the distribution of [aH]naloxone binding sites, bc: 
brachium conjunctivum. Mag.: 200×. 
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FIG. 8. Nucleus tractus solitarius and the spinal nucleus of the trigeminal nerve• A and B are adjacent sections showing the correspondence 
between [aH]naloxone binding and [Leu]enkephalin-positive perikarya in nucleus tractus solitarius. C and D demonstrate the relation between 
a dense streak of [3H]naloxone binding sites and [Leu]enkephalin immunoreactive terminals in the spinal nucleus of the trigeminai nerve, stt: 
spinal tract of the trigeminal nerve. Mag.: 64x. 
relationship between binding sites and opioid systems was 
discernible. Even within a region, the relationship can be 
complex; for example, in caudate-putamen, there was no 
apparent correspondence between the large receptor-rich 
patches and the smaller [Leu]enkephalin patches of  im- 
munoreactivity. In contrast, a good correspondence was 
seen between the subcallosal streaks of  binding sites and 
[Leu]enkephalin immunoreactivity. These relationships 
could not have been determined by comparing sections ob- 
tained from different brains. Adjacent section analysis also 
revealed the distribution of  immunoreactive perikarya in 
some opioid receptor-rich areas of  midbrain and brainstem 
(e.g., interpeduncular nuclear complex, parabrachial nu- 
cleus, and nucleus tractus solitarius). Such observations 
point to the possible existence of  opioid local circuits in 
these regions, although the contribution of  distal opioid 
neurons to these receptor fields also requires evaluation. 
Despite the existence of  impressive opioid peptide- 
receptor associations, as described in the Results section, 
we, as well as other investigators, have observed discrep- 
nacies between the distribution of  opioid peptides and recep- 
tors. Both types of  discrepancy have been noted--ligands 
in the apparent absence of  receptors and vice versa--and 
may be due to relatively trivial technical reasons, or reflect 
authentic phenomena. In the case of  a relative absence of  
receptors (e.g., in globus pallidus), it is possible that the 
physiological receptor has not been labelled, due to 
postmortem lability or the use of  inappropriate ligands 
and/or binding conditions. As an example of the latter, it is 
possible, in the case of  complex polyprotein precursors (e.g., 
the three opioid precursors, the substance P precursors, 
etc.), that the postsynaptic cell may express receptors for 
some products, but not others (e.g., ACTH, but not 
B-endorphin, or substance K, but not substance P). In the 
case of an abundance of  receptors in the absence of  endoge- 
nous ligand, it is possible that the histochemical procedure 
for detecting the latter may not be sufficiently sensitive. As 
an example, the first immunocytochemical studies of  
enkephalin distribution detected very little or no im- 
munoreactivity in cerebral cortex [9, 52, 56] despite the 
existence of  radioimmunoassayable quantities of 
enkephalin-like peptides in this tissue [49,62]. However, as a 
result of  technical improvements, later immunocytochemical 
studies did succeed in localizing these peptides in cortex [ 10, 
11, 23, 24, 33, 34, 50, 55]. Other causes of  discrepancies 
include the detection of  receptors in axonal transit before 
their insertion into the membrane, or simply "spare"  recep- 
tors which may be genetically expressed, but are physio- 
logically unimportant or uncoupled to appropriate effector 
mechanisms. 
Discrepancies between the localization of opioid neuronal 
systems and opioid receptors are not unique to these sys- 
tems; such anomalies have also been observed for substance 
P [45,51], neurotensin [43,63], angiotensin II [35], norepi- 
nephrine [39], and GABA [40,41]. In the case of GABA, at 
least, some of  the anatomical discrepancies have been re- 
solved due to the discovery of  a GABA receptor subtype not 
labelled in the previous autoradiographic studies [61]. 
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The complexity of the association between [3H]naloxone 
binding sites and the multiple opioid systems precludes any 
simple view of opioid peptide-receptor relationships. Al- 
though the [3H]naloxone binding sites appear to reflect 
mostly/~ receptors, there is evidence that r sites are distrib- 
uted identically in rat brain [42]. Thus, there does not appear 
to be a unique association between the multiple opioid 
neuronal systems and opioid receptor subtypes in brain, al- 
though in vitro studies of the receptor selectivity of opioid 
peptides (e.g., dynorphin A for the K receptor; [6, 8, 64]) 
gave rise to a prediction of selective anatomical associations 
(e.g., 8 sites with [Leu]-enkephalin-contalning neurons; 
[12]). Despite the apparent theoretical attractiveness of such 
selective associations, the picture which has emerged is 
much richer in possibilities for regulation of opioid neuro- 
transmission. The availability of multiple opioid receptors 
for interaction with the products of each opioid precursor 
should not be surprising; multiple receptors have already 
been identified for individual ligands, including dopamine, 
norepinephrine, serotonin, GABA, and acetylcholine [53]. 
For some multiple receptor groups, it is clear that the sub- 
types are differentially coupled to effectors (e.g., adenylate 
cyclase), and this appears to be the case for opioid receptor 
subtypes, as well [4,59]. Given the presence of multiple 
opioid receptor subtypes which are differentially coupled to 
effectors, and the occurrence of endogenous ligands which 
have varying affinities for these receptor subtypes, it appears 
that the qualitative and quantitative parameters of opioid 
neurotransmission will be a function of the relative ratios of 
opioid forms released and receptor subtypes present. 
Posttranslational processing thus emerges as a key regula- 
tory event; for example, the release of dynorphin A would 
presumably affect mainly K receptors (unless they were 
scarce), but processing of the peptide to dynorphin A (1-8) 
would improve its relative affinity for /z and 8 receptors 
[8,46]. The relative mix of/z, 8, and r receptors at the synapse 
would determine the physiological outcome of this particular 
processing step (see [60]). Beating on this issue, we have 
shown a clear relationship between the ratios of dynorphin 
A:dynorphin A (1-8) and K:/x opioid receptors in rat and 
guinea pig substantia nigra [26]. Such findings point to the 
need for correlative anatomical/biochemical studies using 
multiple antisera and receptor ligands as tools to uncover 
some of the subtleties of opioid neurotransmission in the 
brain. 
ACKNOWLEDGEMENTS 
We wish to thank Sharon Burke for technical assistance and 
Adele Henry for manuscript preparation. This research was sup- 
ported by NIDA Center grant DA00154, NIDA grant DA02265 and 
the Theophile Raphael grant from the University of Michigan. 
REFERENCES 
1. Atweh, S. and M. J. Kuhar. Autoradiographic localization of 
opiate receptors in rat brain. I. Spinal cord and lower medulla. 
Brain Res 124: 53--67, 1977. 
2. Atweh, S. F. and M. J. Kuhar. Autoradiographic localization of 
opiate receptors in rat brain. II. The brain stem. Brain Res 129: 
1-12, 1977. 
3. Atweh, S. and M. J. Kuhar. Autoradiographic localization of 
opiate receptors in rat brain. III. The telencephalon. Brain Res 
134: 393-405, 1977. 
4. Bowen, W. D., S. Gentleman, M. Herkenham and C. B. Pert. 
Interconverting mu and delta forms of the opiate receptor in rat 
striatal patches. Proc Natl Acad Sci USA 78: 4818--4822, 1981. 
5. Chang, K. J. and P. Cuatrecasas. Heterogeneity and properties 
of opiate receptors. Fed Proc 40" 2729-2734, 1981. 
6. Chavkin, C., I. James and A. Goldstein. Dynorphin is a specific 
endogenous ligand of the kappa opioid receptor. Science 215: 
413-415, 1982. 
7. Comb, M., P. Seeburg, J. Adelman, L. Eiden and E. Herbert. 
Primary structure of the human Met- and Leu-enkephalin pre- 
cursor and its mRNA. Nature 295: 663-666, 1982. 
8. Corbett, A. D., S. J. Paterson, A. T. McKnight, J. Magnan and 
H. Kosterlitz. Dynorphin(l-8) and dynorphin(l-9) are ligands 
for the kappa subtype of opiate receptor. Nature 299: 79-81, 
1982. 
9. Elde, R., T. Hfkfeit, O. Johansson and L. Terenius. Im- 
munohistochemical studies using antibodies to leucine- 
enkephalin: Initial observations on the nervous system of the 
rat. Neuroscience 1: 349--351, 1976. 
10. Finley, J. C. W., J. L. Maderdrut and P. Petrusz. The im- 
munocytochemical localization of enkephalin in the central 
nervous system of the rat, d Comp Neurol 198: 541-565, 1981. 
11. Gall, C,, N. l~lreeh#, H. J, Karten and K.-J. Chang. Localization 
of enkephalin-like immunoreacUwty to identttled axonal and 
neuronal populations of the rat hippocampus. J Comp Neurol 
198: 335-350, 1981. 
12. Goodman, R. R., S. H. Snyder, M. J. Kuhar and W. S. Young, 
III. Differentiation of delta and mu opiate receptor localizations 
by light microscopic autoradiography. Proc Nat! Acad Sci USA 
77: 6239-6243, 1980. 
13. Gubler, U., P. Seeburg, B. J. Hoffman, L. P. Gage and S. 
Udenfriend. Molecular cloning establishes proenkephaiin as 
precursor of enkephalin-containing peptides. Nature 295: 206- 
208, 1982. 
14. Herkenham, M. and C. B. Pert. In vitro autoradiography of 
opiate receptors in rat brain suggests loci of opiatergic path- 
ways. Proc Natl Acad Sci USA 77" 4469-4473, 1980. 
15. Herkenham, M. and C. B. Pert. Mosaic distribution of opiate 
receptors, parafasciular projections and acetylcholinesterase in 
the rat striatum. Nature 291: 415-418, 1981. 
16. Herkenham, M. and C. B. Pert. Light microscopic localization 
of brain opiate receptors: A general autoradiographic method 
which preserves tissue quality. J Neurosci 2:1129-1149, 1982. 
17. Herling, S. and J. H. Woods. Discriminative stimulus effects of 
narcotics: evidence for multiple receptor-mediated actions. Life 
Sci 28: 1571-1584, 1981. 
18. Hiller, J. M., L. M. Angel and E. J. Simon. Multiple opiate 
receptors: Alcohol selectively inhibits binding to delta receptors. 
Science 214: 468--469, 1981. 
19. Iwamoto, E. T. and W. R. Martin. Multiple opiate receptors. 
Med Res Rev 1: 411-440, 1981. 
20. Kakidani, H., Y. Furutani, H. Takehashi, M. Noda, Y. 
Morimoto, T. Hirose, M. Asai, S. Inayama, S. Nakanishi and S. 
Numa. Cloning and sequence analysis of cDNA for porcine 
beta-neo-endorphin/dynorphin precursor. Nature 298: 245-249, 
1982. 
21. Khachaturian, H., M. E. Lewis and S. J. Watson. Co- 
localization of proenkephalin peptides in rat brain neurons. 
Brain Res 279: 369--373, 1983. 
22. Khachaturian, H., M. E. Lewis and S. J. Watson. Enkephalin 
systems in diencephalon and brain stem of the ra:t. J Comp 
Neu1:oi 219: 31fL--320, 1983. 
23. Khachatunan, H., M. E. Lewis and S. J. Watson: Im~ 
munocytochemical studies with antisera against leucine- 
enkephalin and an enkephalin-precursor fragment (BAM-22P) 
in the rat brain. Life Sci 31: 1879-1882, 1982. 
24. Khachaturian, H., M. E. Lewis, V. Hollt and S. J. Watson. 
Telencephalic enkephalinergic systems in the rat brain. J 
Neurosci 3: 844-855, 1983. 
O P I O I D  P E P T I D E - R E C E P T O R  R E L A T I O N S H I P S  47 
25. Khachaturian, H., S. J. Watson, M. E. Lewis, D. Coy, A. 
Goldstein and H. Akil. Dynorphin immunocytochemistry in the 
rat central nervous system. Peptides 3: 941-954, 1982. 
26. Lewis, M. E., R. M. Dores, H. Khachaturian, S. J. Watson and 
H. Akil. Relationship between proportions of dynorphin A 
forms and opioid receptor subtypes in rat and guinea pig sub- 
stantia nigra. International Narcotics Research Conference, 
1984. 
27. Lewis, M. E., H. Khachaturian and S. J. Watson. Visualization 
of opiate receptors and opioid peptides in sequential brain sec- 
tions. Life Sci 31: 1247-1250, 1982. 
28. Lewis, M. E., H. Khachaturian and S. J. Watson. Comparative 
distribution of opiate receptors and three opioid peptide 
neuronal systems in rhesus monkey nervous system. Life Sci 
33: Suppi 1,239-242, 1983. 
29. Lewis, M. E., M. Mishkin, E. Bragin, R. M. Brown, C. B. Pert 
and A. Pert. Opiate receptor gradients in monkey cerebral cor- 
tex: Correspondence with sensory processing hierarchies. Sci- 
ence 211: 1166-1169, 1981. 
30. Lewis, M. E., A. Pert, C. B. Pert and M. Herkenham. Opiate 
receptor localization in rat cerebral cortex. J Comp Neurol 216: 
339-353, 1983. 
31. Lord, J. A. H., A. A. Waterfield, J. Hughes and H. W. Koster- 
litz. Endogenous opioid peptides: Multiple agonists and recep- 
tors. Nature 267: 495--499, 1977. 
32. Mains, R. E., B. A. Eipper and N. Ling. Common precursor to 
corticotrophins and endorphins. Proc Natl Acad Sci USA 74: 
3014--3018, 1977. 
33. McGinty, J. F., D. Van der Kooy and F. E. Bloom. The distri- 
bution and morphology of opioid peptide immunoreactive 
neurons in the cerebral cortex of rats. J Neurosci 4:1104-1117, 
1984. 
34. McGinty, J. F., D. Van der Kooy, L. Y. Koda and F. E. Bloom. 
Enkephalin immunoreactive ceils in frontal, olfactory and lim- 
bic cortex. Anat Rec 202: 125A, 1982. 
35. Mendelsohn, F. A. O., R. Quirion, J. M. Saavedra, G. Aguilera 
and K. J. Catt. Autoradiographic localization of angiotensin II 
receptors in rat brain. Proc Natl Acad Sci USA 81: 1575-1579, 
1984. 
36. Moon Edley, S., L. Hall, M. Herkenham and C. B. Pert. Evo- 
lution of striatal opiate receptors. Brain Res 249: 184-188, 1982. 
37. Nakanishi, S., A. Inoue, T. Kita, M. Nakamura, A. C. Y. 
Chang, S. N. Cohen and S. Numa. Nucleotide sequence of 
cloned cDNA for bovine corticotropin-beta-lipotropin precur- 
sor. Nature 278: 423-427, 1979. 
38. Noda, M., Y. Furutani, H. Takahashi, M. Toyosato, T. Hirose, 
S. Inayama, S. Nakanishi and S. Numa. Cloning and sequence 
analysis of cDNA for bovine adrenal preproenkephalin. Nature 
295: 202-206, 1982. 
39. Palacios, J. M. and M. J. Kuhar. Beta-adrenergic-receptor lo- 
calization by light microscopic autoradiography. Science 208: 
1378-1380, 1980. 
40. Palacios, J. M., J. K. Wamsley and M. J. Kuhar. High affinity 
GABA receptors---autoradiographic localization. Brain Res 
222: 285-307, 1981. 
41. Palacios, J. M., W. Scott Young, III and M. J. Kuhar. Au- 
toradiographic localization of gamma-aminobutyric acid 
(GABA) receptors in the rat cerebellum. Proc Natl Acad Sci 
USA 77: 670-674, 1980. 
42. Quirion, R., W. Bowen, M. Herkenham and C. B. Pert. Visu- 
alization and solubilization of rat brain opiate receptors with a 
"kappa" ligand selectivity pattern. Cell Mol Neurobiol 2: 333- 
345, 1982. 
43. Quirion, R., P. Gaudreau, S. St-Pierre, F. Rioux and C. B. Pert. 
Autoradiographic distribution of [aH]Neurotensin receptors in 
rat brain: visualization by tritium-sensitive f'dm. Peptides 3: 
757-763, 1982. 
44. Quirion, R. and C. B. Pert. Dynorphins: Similar relative poten- 
cies on mu, delta and kappa opiate receptors. Eur J Pharmaeol 
76: 467-468, 1981. 
45. Quirion, R., C. W. Shults, T. W. Moody, C. B. Pert, T. N. 
Chase and T. L. O'Donohue. Autoradiographic distribution of 
substance P receptors in rat central nervous system. Nature 
303: 714--716, 1983. 
46. Quirion, R. and A. S. Weiss. Peptide E and other proenkephalin 
A derived peptides are potent kappa opiate receptor agonists. 
Peptides 4: 445--449, 1983. 
47.. Roberts, J. L. and E. Herbert. Characterization of a common 
precursor to corticotropin and beta-lipotropin: Cell-free syn- 
thesis of the precursor and identification of corticotropin pep- 
tides in the molecule. Proc Natl Acad Sci USA 74" 4826--4830, 
1977. 
48. Roberts, J. L. and E. Herbert. Characterization of a common 
precursor to corticotropin and beta-lipotropin: Identification of 
beta-lipotropin peptides and their arrangement relative to cor- 
ticotropin in the precursor synthesized in a cell-free system. 
Proc Natl Acad Sci USA 74: 5300-5304, 1977. 
49. Rossier, J., T. M. Vargo, S. Minick, N. Ling, F. E. Bloom and 
R. Guillemin. Regional dissociation of beta-endorphin and 
enkephalin contents in rat brain and pituitary. Proc Natl Acad 
Sci USA 74: 5162-5165, 1977. 
50. Sar, M., W. E. Stumpf, R. J. Miller, K-J. Chang and P. Cuat- 
recasas. Immunohistochemical localization of enkephalin in rat 
brain and spinal cord. J Comp Neurol 182: 17-38, 1978. 
51. Shuits, C. W., R. Quirion, R. J. Jensen, T. W. Moody, T. L. 
O'Donohue and T. N. Chase. Autoradiographic localization of 
substance P receptors using l~H substance P. Peptides 3: 1073-- 
1075, 1982. 
52. Simantov, R., M. J. Kuhar, G. R. Uhl and S. H. Snyder. Opioid 
peptide enkephalin: Immunohistochemical mapping in rat cen- 
tral nervous system. Proc Natl Acad Sci USA 74: 2167-2171, 
1977. 
53. Snyder, S. H. Drug and neurotransmitter receptors in the brain. 
Science 224: 22-31, 1984. 
54. Stengaard-Pedersen, K. Comparative mapping of opioid recep- 
tors and enkephalin immunoreactive nerve terminals in the rat 
hippocampus. A radiohistochemical and immunocytochemical 
study. Histochemistry 79: 311-333, 1983. 
55. Wamsley, J. K., W. S. Young, III and M. J. Kuhar. Immunohis- 
tochemical localization of enkephalin in rat forebrain. Brain Res 
190: 153-174, 1980. 
Watson, S. J., H. Akil, S. O. Sullivan and J. D. Barchas. Im- 
munocytochemical localization of methionine-enkephalin: Pre- 
liminary observations. Life Sci 25: 733-738, 1977. 
Watson, S. J., H. Akil and J. M. Walker. Anatomical and 
biochemical studies of the opioid peptides and related sub- 
stances in the brain. Peptides 1: Suppl 1, 11-20, 1980. 
Watson, S. J., H. Khachaturian, H. Akil, D. Coy and A. Gold- 
stein. Comparison of the distribution of dynorphin systems and 
enkephalin systems in brain. Science 218: 1134--1136, 1982. 
Werz, M. A., M. E. Lewis, D. S. Grega, S. J. Watson and R. L. 
MacDonald. Heterogeneity of opioid receptors on dorsal root 
ganglion neurons in culture: A combined autoradiographic and 
electrophysiological study. Soc Neurosci Abstr 10: 585, 1984. 
Werz, M. A. and R. L. MacDonald. Heterogenous sensitivity of 
cultured dorsal root ganglion neurons to opioid peptides selec- 
tive for mu and delta-opiate receptors. Nature 299: 730-733, 
1982. 
Wilkin, G. P., A. L. Hudson, D. R. Hill and N. G. Bowery. 
Autoradiographic localization of GABAB receptors in rat cere- 
bellum. Nature 294: 584--587, 1981. 
Yang, H.-Y., J. S. Hong and E. Costa. Regional distribution of 
leu and met enkephaiin in rat brain. Neuropharmacology 16: 
303-307, 1977. 
Young, W. Scott, III and M. J. Kuhar. Neurotensin receptor 
localization by light microscopic autoradiography in rat brain. 
Brain Res 206: 273-285, 1981. 
Young, E., J. M. Walker, R. Houghten and H. Akil. 
['~H]dynorphin A binds selectively to guinea pig brain. Eur J 
Pharmacol 91: 327-328, 1983. 
56. 
57. 
58. 
59. 
60. 
61. 
62. 
63. 
64. 
